Supplement Dose Escalation Trials Help Foster Success – NCCAM’s Berman
This article was originally published in The Tan Sheet
Executive Summary
Initial dose escalation trials will improve the success rate of dietary supplement clinical trials, according to director of NCCAM's Office of Clinical & Regulatory Affairs, Jonathan Berman, MD, PhD
You may also be interested in...
Inadequate Plant Characterization Plagues Trials, AERs – UCLA’s Hardy
Preliminary data suggests the characterization of plants cited in adverse event reports published in medical literature is "woefully inadequate," according to Mary Hardy, MD, University of California - Los Angeles, Center for Dietary Research in Botanicals
Saw Palmetto Trial At Higher Dose Would Be “Logical” – NCCAM’s Miller
A dose escalation study is a "very logical next step" for saw palmetto researchers to take, according to Heather Miller, PhD, of NCCAM's Division of Extramural Research & Training
Inconclusive St. John’s Wort Trial Prompts Queries On Study Design, Setting
The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association